test

Rogerio C. Lilenbaum MD

Professor of Medicine (Medical Oncology); Chief Medical Officer of Smilow Cancer Hospital

Clinical Interests

lung cancer; lung cancer treatment in older patients


Board Certifications

1995
Internal Medicine, Board Certified
1997
Medical Oncology, Board Certified
1998
Hematology (Internal Medicine), Board Certified

Patient Care Locations

rogerio_lilenbaumfaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
LungLung Cancer Mutation Consortium Protocol
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), (S1206/NCI Study Number 8811)
LungA Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer
LungPhase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects with Previously Untreated Extensive-stage Small-cell Lung Cancer
Bladder, Breast - Female, Lung, Pancreas, and StomachA Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

More Clinical Trials...

Edit Profile